狄诺塞麦能随便停药吗？

Denosumab (denosumab) and bisphosphonates are the most commonly used osteoporosis treatments, among which denosumab (denosumab) is a RANK ligand (RANKL) inhibitor that inhibits osteoclast recruitment and differentiation. It is a very effective drug for treating bone metastasis.

Clinical studies have shown that after discontinuation of denosumab (denosumab), bone resorption increases, and the increased bone mass during treatment is lost rapidly, and the effects of denosumab (denosumab) are reversible.

It is inferred that the decreased inhibition of bone turnover results from counterregulation by increased RANKL production, and that when the effects of denosumab eventually wear off, increased RANKL production and potential aggregation will lead to a rebound in bone turnover that predisposes at least some patients to hypercalcemia.

Therefore, it is best for patients not to stop taking the medicine at will. If no side effects occur, they still need to inject on time and quantitatively according to the doctor's instructions.

Physicians should evaluate the need to continue denosumab treatment in patients who develop serious infections while taking denosumab. Osteonecrosis of the jaw often occurs with tooth extraction and local infection that delays healing. A routine oral examination should be performed before starting treatment with denosumab (denosumab), and good oral hygiene should be maintained after treatment is started. If a patient develops osteonecrosis of the jaw, treatment for osteonecrosis of the jaw may worsen the condition, and discontinuation of the medication should be considered at this time.

Denosumab (denosumab) needs to be injected subcutaneously and cannot be given as an intravenous infusion, intramuscular infusion or intradermal injection. Giant cell tumor of bone: 120 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. Administer calcium and vitamin D appropriately to prevent hypocalcemia. Bone metastases from solid tumors: 120 mg subcutaneously in the upper arm, thigh, or abdomen every 4 weeks. Malignant hypercalcemia: 20 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen. (denosumab) injection is best done with the involvement of a healthcare professional.

Recommended related hot articles: /newsDetail/77923.html